Log in or Sign up for Free to view tailored content for your specialty!
Hematology News
New gene therapy appears safe, feasible for sickle cell disease
ORLANDO — Significant induction of fetal hemoglobin after the infusion of CD34-positive cells occurred among a small cohort of patients with sickle cell disease, according to data from a phase 1 gene therapy feasibility study presented at ASH Annual Meeting and Exposition.
FDA approves first generic versions of apixaban
The FDA announced it approved two applications for the first generic versions of apixaban tablets to reduce risk for stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Log in or Sign up for Free to view tailored content for your specialty!
Fragmentation of care common among young adults with sickle cell disease
ORLANDO — Young adults with sickle cell disease experienced fragmentation of health care during the transition period after childhood, according to the results of a retrospective study presented at ASH Annual Meeting and Exposition.
VIDEO: Efgartigimod safe, effective in primary immune thrombocytopenia
ORLANDO — A 3-week treatment cycle of efgartigimod, a neonatal Fc receptor antagonist, was well tolerated and effective in patients with primary immune thrombocytopenia, according to phase 2 data presented at the ASH Annual Meeting and Exposition.
Hemophilia A patients ‘highly satisfied’ after switching to emicizumab
ORLANDO — Patients with hemophilia A who had higher annual bleeding rates and poor adherence to infusion-based prophylaxis were more likely to switch treatment to emicizumab and were “highly satisfied with this switch,” according to researchers at the ASH Annual Meeting and Exposition.
ASH presents Scholar Awards to fellows, junior faculty
ASH announced the recipients of its 2019 Scholar Awards.
VIDEO: Apixaban demonstrates benefit over other anticoagulation treatments
ORLANDO — Apixaban reduced the risk for recurrent venous thromboembolism compared with low-molecular-weight heparin and warfarin, according to results of a large epidemiology study presented at the ASH Annual Meeting and Exposition.
VIDEO: Aspirin linked to bleeding events in patients receiving direct oral anticoagulants
ORLANDO — In this video at the ASH Annual Meeting and Exposition, Thein H. Oo, MD, FRCPE, FACP, reviews a study that showed the addition of aspirin to direct oral anticoagulants for venous thromboembolism or non-valvular atrial fibrillation was linked to an increase in bleeding events.
VIDEO: Crizanlizumab may reduce hospitalization in sickle cell disease
ORLANDO — Julie Kanter, MD, from the division of hematology-oncology at the University of Alabama-Birmingham, discussed the first-ever targeted FDA-approved drug for sickle cell disease, crizanlizumab, in a video at the ASH Annual Meeting and Exposition.
UK authority clears Roche acquisition of Spark
The U.K. Competition and Markets Authority has cleared Roche’s pending acquisition of Spark Therapeutics, ruling the deal would not negatively affect competition, according to a press release.
-
Headline News
‘Truly alarming’: Life expectancy gap in the US now up to 20 years
November 22, 20243 min read -
Headline News
Autoantibodies present in long COVID, but not a ‘smoking gun’ for new autoimmune disease
November 25, 20242 min read -
Headline News
Cardiovascular disease deaths rising among younger adults living in rural areas
November 15, 20243 min read
-
Headline News
‘Truly alarming’: Life expectancy gap in the US now up to 20 years
November 22, 20243 min read -
Headline News
Autoantibodies present in long COVID, but not a ‘smoking gun’ for new autoimmune disease
November 25, 20242 min read -
Headline News
Cardiovascular disease deaths rising among younger adults living in rural areas
November 15, 20243 min read